Search Legislation

Council Directive of 26 June 1990 on animal health conditions governing the movement and import from third countries of equidae (90/426/EEC) (repealed)

 Help about what version

What Version

 Help about advanced features

Advanced Features

 Help about UK-EU Regulation

Legislation originating from the EU

When the UK left the EU, legislation.gov.uk published EU legislation that had been published by the EU up to IP completion day (31 December 2020 11.00 p.m.). On legislation.gov.uk, these items of legislation are kept up-to-date with any amendments made by the UK since then.

Close

This item of legislation originated from the EU

Legislation.gov.uk publishes the UK version. EUR-Lex publishes the EU version. The EU Exit Web Archive holds a snapshot of EUR-Lex’s version from IP completion day (31 December 2020 11.00 p.m.).

Changes over time for: Council Directive of 26 June 1990 on animal health conditions governing the movement and import from third countries of equidae (90/426/EEC) (repealed) (Annexes only)

 Help about opening options

Version Superseded: 12/08/2010

Status:

EU Directives are published on this site to aid cross referencing from UK legislation. Since IP completion day (31 December 2020 11.00 p.m.) no amendments have been applied to this version.

ANNEX AU.K.COMPULSORILY NOTIFIABLE DISEASES

The following diseases are compulsorily notifiable:

  • Dourine

  • Glanders

  • Equine encephalomyelitis (of all types, including VEE)

  • Infectious anaemia

  • Rabies

  • Anthrax

  • African horse sickness

  • Vesicular stomatitis

[F1ANNEX B U.K.

ANNEX C U.K.

]

[F2ANNEX D U.K. AFRICAN HORSE SICKNESS DIAGNOSIS

Reagents for the enzyme-linked immunosorbent assays (ELISA) described below may be obtained from the European Community Reference Laboratory or the OIE Reference Laboratories for African horse sickness.

1. COMPETITIVE ELISA FOR THE DETECTION OF ANTIBODIES TO AFRICAN HORSE SICKNESS VIRUS (AHSV) (PRESCRIBED TEST) U.K.

Competitive ELISA is used to detect specific AHSV antibodies in sera from any species of equidae. The broad spectrum, polyclonal, immune anti-AHSV guinea-pig serum (hereinafter guinea-pig antiserum ) is serogroup specific and is able to detect all known serotypes of AHS virus.

The principle of the test is the interruption of the reaction between AHSV antigen and a guinea-pig antiserum by a test serum sample. AHSV antibodies in the test serum sample will compete with those in the guinea-pig antiserum resulting in a reduction in the expected colour (following the addition of enzyme labelled anti-guinea-pig antibody and substrate). Sera can be tested at a single dilution of 1 in 5 (spot test method) or may be titrated (serum titration method) to give dilution end-points. Inhibition values higher than 50 % may be regarded as positive.

The test protocol described hereinafter is used in the Regional Reference Laboratory for African horse sickness in Pirbright, United Kingdom.

1.1. Test procedure U.K.

1.1.1. Preparation of plates U.K.
1.1.1.1. Coat ELISA plates with AHSV antigen extracted from infected cell cultures and diluted in carbonate/bicarbonate buffer, pH 9,6. Incubate the ELISA plates overnight at 4 °C. U.K.
1.1.1.2. Wash plates three times by flooding and emptying the wells with phosphate buffered saline (PBS), pH 7,2 to 7,4 pH, and blot dry on adsorbent paper. U.K.
1.1.2. Control wells U.K.
1.1.2.1. Titrate the positive control sera in a twofold dilution series, from 1 in 5 to 1 in 640, across column 1 in blocking buffer (PBS containing 0,05 % (v/v) Tween-20, 5,0 % (w/v) skimmed-milk powder (Cadbury's Marvel TM ) and 1 % (v/v) adult bovine serum) to give a final volume of 50 μl/well. U.K.
1.1.2.2. Add 50 μl of the negative control serum at a dilution of 1 in 5 (10 μl serum + 40 μl blocking buffer) to wells A and B of column 2. U.K.
1.1.2.3. Add 100 μl/well of blocking buffer to wells C and D of column 2 (blank). U.K.
1.1.2.4. Add 50 μl of blocking buffer to wells E, F, G and H of column 2 (guinea pig control). U.K.
1.1.3. Spot test method U.K.
1.1.3.1. Add a 1 in 5 dilution of each test serum in blocking buffer to duplicate wells of columns 3 to 12 (10 μl sera + 40 μl blocking buffer). U.K.

or

1.1.4. Serum titration method U.K.
1.1.4.1. Prepare a twofold dilution series of each test sample (1 in 5 to 1 in 640) in blocking buffer across eight wells of single columns (3 to 12). U.K.

then

1.1.5. Add 50 μl of guinea pig antisera, pre-diluted in blocking buffer, to all wells except the blank wells of the ELISA plate (all wells now contain a final volume of 100 μl). U.K.
1.1.5.1. Incubate for 1 hour at 37 °C on an orbital shaker. U.K.
1.1.5.2. Wash plates three times and blot dry as before. U.K.
1.1.5.3. Add 50 μl of rabbit anti-guinea-pig horseradish peroxidase (HRP) conjugate pre-diluted in blocking buffer to each well. U.K.
1.1.5.4. Incubate for 1 hour at 37 °C on an orbital shaker. U.K.
1.1.5.5. Wash plates three times and blot dry as before. U.K.
1.1.6. Chromogen U.K.

Prepare the chromogen OPD (OPD = ortho-phenyldiamine) solution according to the manufacturers instructions (0,4 mg/ml in sterile distilled water) just before use. Add substrate (hydrogen peroxide = H 2 O 2 ) to give a final concentration of 0,05 % (v/v) (1 in 2000 of a 30 % solution of H 2 O 2 ). Add 50 μl of the OPD solution to each well and leave plates on the bench for 10 minutes at ambient temperature. Stop the reaction by the addition of 50 μl/well of 1M sulphuric acid (H 2 SO 4 ).

1.1.7. Reading U.K.

Read spectrophotometrically at 492 nm.

1.2. Expression of results U.K.

1.2.1. Using a software package print out the optical density (OD) values, and the percentage inhibition (PI) for test and control sera based on the mean value recorded in the four guinea pig control wells. The data expressed as OD and PI values are used to determine whether the test has performed within acceptable limits. The upper control limits (UCL) and lower control limits (LCL) for the guinea pig control are between OD values 1,4 and 0,4 respectively. The end-point titre for the positive control based on 50 % PI should be 1 in 240 (within a range from 1 in 120 to 1 in 480). Any plate that fails to conform to the above criteria must be rejected. However, if the positive control serum titre is greater than 1 in 480 and the test samples are still negative then the negative test samples can be accepted. U.K.

The duplicate negative control serum wells and the duplicate blank wells should record PI values between + 25 % and – 25 %, and between + 95 % and + 105 %, respectively. Failure to be within these limits does not invalidate the plate but does suggest that background colour is developing.

1.2.2. The diagnostic threshold (cut-off value) for test sera is 50 % (PI 50 %). Samples recording PI values greater than 50 % are recorded as positive. Samples recording PI values lower than 50 % are recorded as negative. U.K.

Samples that record PI values above and below the threshold for the duplicate wells are considered doubtful. Such samples may be re-tested in the spot test and by titration. Positive samples may also be titrated to provide an indication of the degree of positivity.

Spot test layout
–ve cont

=

negative control.

+ve cont

=

positive control.

GP cont

=

guinea pig control.

1 2 3 4 5 6 7 8 9 10 11 12
+ve cont. Test sera
A 1:5 –ve cont. 31 32 33 34 35 36 37 38 39 40
B 1:10 –ve cont. 31 32 33 34 35 36 37 38 39 40
C 1:20 Blank
D 1:40 Blank
E 1:80 GP cont.
F 1:160 GP cont.
G 1:320 GP cont. 1 2 3 4 5 6 7 8 9 10
H 1:640 GP cont. 1 2 3 4 5 6 7 8 9 10
Test sera
–ve cont

=

negative control.

+ve cont

=

positive control.

GP cont

=

guinea pig control.

1 2 3 4 5 6 7 8 9 10 11 12
+ve cont. Test sera
A 1:5 –ve cont. 1:5 1:5
B 1:10 –ve cont. 1:10 1:10
C 1:20 Blank 1:20 1:20
D 1:40 Blank 1:40 1:40
E 1:80 GP cont. 1:80 1:80
F 1:160 GP cont. 1:160 1:160
G 1:320 GP cont. 1:320 1:320
H 1:640 GP cont. 1:640 1:640

2. INDIRECT ELISA FOR THE DETECTION OF ANTIBODIES TO AFRICAN HORSE SICKNESS VIRUS (AHSV) (PRESCRIBED TEST) U.K.

The test described hereinafter is in accordance with the test description in Chapter 2.1.11 of the OIE Manual of Standards for Diagnostic Tests and Vaccines , fourth edition, 2000.

The recombinant VP7 protein has been used as antigen for AHS virus antibody determination with a high index of sensitivity and specificity. Other advantages are that it is stable and not infective.

2.1. Test procedure U.K.

2.1.1. Solid phase U.K.
2.1.1.1. ELISA plates are coated with recombinant AHSV-4 VP7 diluted in carbonate/bicarbonate buffer, pH 9,6. Incubate plates overnight at 4 °C. U.K.
2.1.1.2. Wash the plates five times with distilled water containing 0,01 % (v/v) Tween 20 (washing solution). Gently tap the plates onto absorbent material to remove any residual wash. U.K.
2.1.1.3. Block the plates with phosphate buffered saline (PBS) + 5 % (w/v) skimmed milk (Nestlé Dry Skim Milk TM ), 200 μl/well, for 1 hour at 37 °C. U.K.
2.1.1.4. Remove the blocking solution and gently tap the plates onto absorbent material. U.K.
2.1.2. Test samples U.K.
2.1.2.1. Serum samples to be tested, and positive and negative control sera, are diluted 1 in 25 in PBS + 5 % (w/v) skimmed milk + 0,05 % (v/v) Tween 20, 100 μl per well. Incubate for 1 hour at 37 °C. U.K.

For titration, make a twofold dilution series from 1 in 25 (100 μl/well), one serum per plate column, and do the same with positive and negative controls. Incubate for 1 hour at 37 °C.

2.1.2.2. Wash the plates as described in step 2.1.1.2. U.K.
2.1.3. Conjugate U.K.
2.1.3.1. Dispense 100 μl/well of horseradish-peroxidase (HRP) -conjugated anti-horse gamma-globulin diluted in PBS + 5 % milk + 0,05 % Tween 20, pH 7,2. Incubate for 1 hour at 37 °C. U.K.
2.1.3.2. Wash the plates as described in step 2.1.1.2. U.K.
2.1.4. Cromogen/Substrate U.K.
2.1.4.1. Add 200 μl/well of chromogen/substrate solution (10 ml of 80,6 mM DMAB (dimethyl aminobenzaldehyde) + 10 ml of 1,56 mM MBTH (3-methyl-2-benzo-thiazoline hydrazone hydrochlorid) + 5 μl H 2 O 2 ) U.K.

Colour development is stopped by adding 50 μl of 3N H 2 SO 4 after approximately 5 to 10 minutes (before the negative control begins to be coloured).

Other chromogens such as ABTS (2,2'-Azino-bis-[3-ethylbenzothiazoline-6-sulphonic acid]), TMB (tetramethyl benzidine), or OPD (ortho-phenyldiamine) can also be used.

2.1.4.2. Read the plates at 600 nm (or 620 nm). U.K.

2.2. Interpretation of the results U.K.

2.2.1. Calculate the cut-off value by adding 0,6 to the value of the negative control (0,6 is the standard deviation derived with a group of 30 negative sera). U.K.
2.2.2. Test samples giving absorbance values lower than the cut-off are regarded as negative. U.K.
2.2.3. Test samples giving absorbance values greater than the cut-off + 0,15 are regarded as positive. U.K.
2.2.4. Test samples giving intermediate absorbance values are doubtful and a second technique must be employed to confirm the result. U.K.

3. BLOCKING ELISA FOR THE DETECTION OF ANTIBODIES TO AFRICAN HORSE SICKNESS VIRUS (AHSV) (PRESCRIBED TEST) U.K.

The blocking ELISA is designed to detect specific AHSV antibodies in sera from any susceptible species. VP7 is the major, antigenic, viral protein of AHSV, and is conserved within the nine serotypes. Because the monoclonal antibody (Mab) is also directed against the VP7, the assay will give a high level of sensitivity and specificity. Further, the recombinant VP7 antigen is completely innocuous and therefore guarantees a high degree of safety.

The principal of the test is the interruption of the reaction between the recombinant VP7, as the antigen bound to the ELISA plate and the conjugated Mab specific for the VP7. Antibody in the test sera will block the reaction between the antigen and the Mab resulting in a reduction in colour.

The test described hereinafter is carried out in the European Community Reference Laboratory for African horse sickness in Algete, Spain.

3.1. Test procedure U.K.

3.1.1. ELISA plates U.K.
3.1.1.1. Coat ELISA plates with recombinant AHSV-4 VP7 diluted in carbonate/bicarbonate buffer, pH 9,6. Incubate overnight at 4 °C. U.K.
3.1.1.2. Wash the plates five times with phosphate buffered saline (PBS) containing 0,05 % (v/v) Tween 20 (PBST). U.K.
3.1.1.3. Stabilise the plate by treatment with a stabilising solution (in order to allow long term storage at 4 °C without loss of activity) and blot dry onto adsorbent material. U.K.
3.1.2. Test samples and controls U.K.
3.1.2.1.
For screening: dilute test sera and controls 1 in 10 directly on the plate in PBST to give a final volume 100 μl/well. Incubate for 1 hour at 37 °C.
3.1.2.2.
For titration: prepare a twofold dilution series of test sera and positive controls (100 μl/well) from 1 in 10 to 1 in 1 280 across eight wells. Negative control is tested at 1 in 10 dilution.
3.1.3. Conjugate U.K.

Add 50 μl/well of pre-diluted horseradish-peroxidase (HRP) -conjugated Mab (monoclonal antibodies specific for VP7) to each well and mix gently to ensure homogeneity. Incubate for 30 minutes at 37 °C.

3.1.4. Wash the plates five times with PBST and blot dry as above. U.K.
3.1.5. Chromogen/Substrate U.K.

Add 100 μl/well of chromogen/substrate solution (1 ml of ABTS (2,2'-Azino-bis-[3-ethylbenzothiazoline-6-sulphonic acid]) 5 mg/ml + 9 ml of substrate buffer (0,1 M Phosphate-Citrate buffer of pH 4 containing 0,03 % H 2 O 2 ] and incubate for 10 minutes at room temperature. Colour development is stopped by adding 100 μl/well of 2 % (w/v) SDS (sodium dodecyl sulphate).

3.1.6. Reading U.K.

Read at 405 nm in an ELISA reader.

3.2. Interpretation of the results U.K.

3.2.1. Assay validation U.K.

The test is valid when the optical density (OD) of negative control (NC) is higher than 1,0 and the OD of positive control (PC) is lower than 0,2.

3.2.2. Cut-off calculation U.K.
Positive cut-off

=

Negative cut-off

=

Where, NC is the OD of the negative control and PC the OD of positive control.

3.2.3. Interpretation of results U.K.

Samples with OD lower than positive cut-off should be considered as positives to AHSV antibodies.

Samples with OD higher than negative cut-off should be considered negatives for AHSV antibodies.

Samples with OD between these two values should be considered doubtful and the animals re-sampled after two to three weeks.]

Back to top

Options/Help

Print Options

Close

Legislation is available in different versions:

Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.

Original (As adopted by EU): The original version of the legislation as it stood when it was first adopted in the EU. No changes have been applied to the text.

Point in Time: This becomes available after navigating to view revised legislation as it stood at a certain point in time via Advanced Features > Show Timeline of Changes or via a point in time advanced search.

Close

See additional information alongside the content

Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.

Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.

Close

Opening Options

Different options to open legislation in order to view more content on screen at once

Close

More Resources

Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:

  • the original print PDF of the as adopted version that was used for the EU Official Journal
  • lists of changes made by and/or affecting this legislation item
  • all formats of all associated documents
  • correction slips
  • links to related legislation and further information resources
Close

Timeline of Changes

This timeline shows the different versions taken from EUR-Lex before exit day and during the implementation period as well as any subsequent versions created after the implementation period as a result of changes made by UK legislation.

The dates for the EU versions are taken from the document dates on EUR-Lex and may not always coincide with when the changes came into force for the document.

For any versions created after the implementation period as a result of changes made by UK legislation the date will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. For further information see our guide to revised legislation on Understanding Legislation.

Close

More Resources

Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:

  • the original print PDF of the as adopted version that was used for the print copy
  • correction slips

Click 'View More' or select 'More Resources' tab for additional information including:

  • lists of changes made by and/or affecting this legislation item
  • confers power and blanket amendment details
  • all formats of all associated documents
  • links to related legislation and further information resources